Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron M Etra

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Blood|August 22, 2025
Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHDAaron M Etra, James L M Ferrara, John E Levine
Transplantation and Cellular Therapy|March 8, 2024
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical CommitteeZainab Shahid, Aaron M Etra, John E Levine, et al.
Blood Immunology & Cellular Therapy|May 15, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRMYu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, et al.
Transplantation and Cellular Therapy|December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk GroupNikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.
Blood Advances|July 1, 2025
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGICYu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, et al.
Blood Advances|December 22, 2020
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsinStephanie C Gergoudis, Zachariah DeFilipp, Umut Özbek, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Blood|August 22, 2025
Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHDAaron M Etra, James L M Ferrara, John E Levine
Transplantation and Cellular Therapy|March 8, 2024
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical CommitteeZainab Shahid, Aaron M Etra, John E Levine, et al.
Blood Immunology & Cellular Therapy|May 15, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRMYu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, et al.
Transplantation and Cellular Therapy|December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk GroupNikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.
Blood Advances|July 1, 2025
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGICYu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, et al.
Blood Advances|December 22, 2020
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsinStephanie C Gergoudis, Zachariah DeFilipp, Umut Özbek, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Pageof 2